Ge Long Hui·2025-12-12 11:45Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for the ketoprofen patch in China, indicating a significant step in the development of this pain relief medication [1] Group 1: Clinical Trial Approval - The ketoprofen patch is intended for clinical trials in China, specifically for Phase III trials once conditions are met [1] - The drug is a chemical medication primarily aimed at treating pain and inflammation associated with various conditions, including lower back pain, osteoarthritis, and rheumatoid arthritis [1] Group 2: Research and Development Investment - As of October 2025, the cumulative R&D investment for the ketoprofen patch by the group is approximately RMB 960,000 (unaudited) [1] - The projected sales revenue for ketoprofen formulations in China for 2024 is estimated to be around RMB 91.16 million [1]